Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · View financials
Decision snapshot: INSP stock price vs RMD: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at RMD's multiple
Needs RMD P/E.
Implied fair value · at INSP's multiple
Needs INSP P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: INSP FY 2025 (ended Dec 31, 2025) · RMD FY 2026 (ended Jun 30, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
Inspire Medical Systems, Inc. · implied price per share
Bear
$14.19
Base
$16.69
Bull
$19.20
ResMed Inc. · implied price per share
Bear
$111.85
Base
$131.59
Bull
$151.33
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.04x
0.10x
Net debt / EBITDA
Leverage against operating earnings
-4.05x
-0.38x
Cash and equivalents
Liquid reserves on the balance sheet
$308.27M
$1.47B
Total debt
Interest-bearing obligations outstanding
$33.69M
$659.37M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe INSP can materially expand operating and EBITDA margins (currently 4.5% and 7.5%) toward RMD levels while sustaining its 28.5% revenue growth, then buy because margin expansion would justify the current high P/E (45.4x); otherwise reduce or avoid exposure because RMD-implied P/E yields a $47.54 price (-40.1% downside).
INSP's current price of $79.40 implies a P/E of 45.4x, versus a RMD-implied price of $47.54 (RMD P/E 27.2x), implying a -40.1% downside to RMD-implied valuation. The gap is driven by a high P/E and EV/EBITDA (32.2x) relative to ResMed, while P/S (2.9x) and EV/Revenue (2.4x) are materially below RMD, indicating mixed market signals about revenue quality and profitability.
Supporting Metrics
